Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.58 |
| ▸ | DRD1 | P21728 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6666143 | 1.00 | ALDH1A1 (0.58) | ALDH1A1LMNACYP2D6MAPK1CYP3A4 | |
| SCHEMBL2579539 | 0.87 | LMNA (0.72) | ALDH1A1LMNACYP2D6MAPK1CYP3A4 | |
| SCHEMBL11036914 | 0.83 | LTA4H (0.77) | ALDH1A1LMNACYP2D6MAPK1CYP3A4 | |
| SCHEMBL613704 | 0.83 | LTA4H (0.77) | ALDH1A1LMNACYP2D6MAPK1CYP3A4 | |
| SCHEMBL6293359 | 0.83 | ALDH1A1 (0.48) | ALDH1A1LMNACYP2D6MAPK1CYP3A4 | |
| SCHEMBL9779468 | 0.83 | SIGMAR1 (0.71) | ALDH1A1SIGMAR1MEN1KMT2AHSP90AA1 | |
| SCHEMBL15759224 | 0.83 | ALDH1A1 (0.51) | ALDH1A1HIF1ATSHRKDM4ELTA4H | |
| SCHEMBL17888675 | 0.83 | ALDH1A1 (0.48) | ALDH1A1LMNACYP2D6MAPK1CYP3A4 | |
| SCHEMBL17888676 | 0.83 | ALDH1A1 (0.48) | ALDH1A1LMNACYP2D6MAPK1CYP3A4 | |
| SCHEMBL6293360 | 0.83 | ALDH1A1 (0.48) | ALDH1A1LMNACYP2D6MAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362151-A1 | COMPOSITIONS AND METHODS FOR REDUCTION OF KETONES, ALDEHYDES AND IMINIUMS, AND PRODUCTS PRODUCED THEREBY | BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170349561-A1 | SYNTHESIS OF NOVEL IONIC LIQUIDS FROM LIGNIN-DERIVED COMPOUNDS | UNITED STATES DEPARTMENT OF ENERGY | 2017-12-07 | — | — | US | disclosed |
| US-9765044-B2 | Synthesis of novel ionic liquids from lignin-derived compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160031843-A1 | SYNTHESIS OF NOVEL IONIC LIQUIDS FROM LIGNIN-DERIVED COMPOUNDS | UNITED STATES DEPARTMENT OF ENERGY | 2016-02-04 | — | — | US | disclosed |
| US-8580990-B2 | Gold catalyzed hydroamination of alkynes and allenes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110166349-A1 | GOLD CATALYZED HYDROAMINATION OF ALKYNES AND ALLENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2121598-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008076754-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2008-06-26 | — | — | WO | disclosed |
| US-6359174-B1 | REACTING ALLYL REACTANT WITH ACID CHLORIDE IN PRESENCE OF LEWIS ACID CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031843-A1 | SYNTHESIS OF NOVEL IONIC LIQUIDS FROM LIGNIN-DERIVED COMPOUNDS | DCXR, LCT, LARS1 | ALDH1A1 185/4885LMNA 128/4885CYP2D6 4475/4885 |
| US-20170362151-A1 | COMPOSITIONS AND METHODS FOR REDUCTION OF KETONES, ALDEHYDES AND IMINIUMS, AND PRODUCTS PRODUCED THEREBY | ADH1A, ADH1C, ADH5 | ALDH1A1 11/4885LMNA 321/4885CYP2D6 1065/4885 |
| US-20110166349-A1 | GOLD CATALYZED HYDROAMINATION OF ALKYNES AND ALLENES | AOC3, AOC2, AOC1 | ALDH1A1 202/4885LMNA 2925/4885CYP2D6 1661/4885 |
| US-20170349561-A1 | SYNTHESIS OF NOVEL IONIC LIQUIDS FROM LIGNIN-DERIVED COMPOUNDS | LSS, DCXR, MYB | ALDH1A1 2369/4885LMNA 101/4885CYP2D6 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.